CL2015003200A1 - Potenciador de inhibidores del homólogo de zeste - Google Patents

Potenciador de inhibidores del homólogo de zeste

Info

Publication number
CL2015003200A1
CL2015003200A1 CL2015003200A CL2015003200A CL2015003200A1 CL 2015003200 A1 CL2015003200 A1 CL 2015003200A1 CL 2015003200 A CL2015003200 A CL 2015003200A CL 2015003200 A CL2015003200 A CL 2015003200A CL 2015003200 A1 CL2015003200 A1 CL 2015003200A1
Authority
CL
Chile
Prior art keywords
zeste
counterpart
inhibitor enhancer
ezh2
enhancer
Prior art date
Application number
CL2015003200A
Other languages
English (en)
Inventor
Jr Charles William Blackledge
Joelle Lorraine Burgess
Neil W Johnson
Jiri Kasparec
Steven David Knight
Iii Louis V Lafrance
Juan I Luengo
William Henry Miller
Kenneth Allen Newlander
Stuart Paul Romeril
Mark Schulz
Dai-Shi Su
Xinrong Tian
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2015003200A1 publication Critical patent/CL2015003200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

COMPUESTOS DERIVADOS DE N-((2-OXO-1,2-DIHIDROPIRIDIN-3-IL)METIL)-CARBOXAMIDA, INHIBIDORES DEL POTENCIADOR DEL HOMOLOGO ZESTE 2 (EZH2); COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; METODO PARA TRATAR CANCER; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR EZH2.
CL2015003200A 2013-04-30 2015-10-30 Potenciador de inhibidores del homólogo de zeste CL2015003200A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361817436P 2013-04-30 2013-04-30
US201361842038P 2013-07-02 2013-07-02
US201361907024P 2013-11-21 2013-11-21
US201461936460P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
CL2015003200A1 true CL2015003200A1 (es) 2016-04-22

Family

ID=50877537

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003200A CL2015003200A1 (es) 2013-04-30 2015-10-30 Potenciador de inhibidores del homólogo de zeste

Country Status (20)

Country Link
US (2) US9505745B2 (es)
EP (1) EP2991980B1 (es)
JP (1) JP6373973B2 (es)
KR (1) KR20160003115A (es)
CN (1) CN105308038B (es)
AU (1) AU2014261075B2 (es)
BR (1) BR112015027527A2 (es)
CA (1) CA2910873A1 (es)
CL (1) CL2015003200A1 (es)
DO (1) DOP2015000270A (es)
EA (1) EA030196B1 (es)
ES (1) ES2717680T3 (es)
HK (1) HK1214815A1 (es)
MX (1) MX2015015144A (es)
NZ (1) NZ630205A (es)
PE (1) PE20151981A1 (es)
PH (1) PH12015502414A1 (es)
SG (1) SG11201508203TA (es)
WO (1) WO2014177982A1 (es)
ZA (1) ZA201507398B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2812001B1 (en) * 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ630205A (en) * 2013-04-30 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Enhancer of zeste homolog 2 inhibitors
AU2014288839B2 (en) 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
JP6479029B2 (ja) 2014-02-06 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
KR20170068603A (ko) * 2014-10-28 2017-06-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
TW201636344A (zh) * 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
AU2016312514A1 (en) 2015-08-24 2018-03-15 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
RS59763B1 (sr) 2015-11-19 2020-02-28 Jiangsu hengrui medicine co ltd Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
US10604531B2 (en) * 2016-05-05 2020-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US20170337814A1 (en) * 2016-05-20 2017-11-23 Donald Edward Morgan Safety alerting drivers device and system
MX2019002616A (es) 2016-09-07 2019-09-18 Shanghai Haihe Pharmaceutical Co Ltd Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
PT3746446T (pt) 2018-01-31 2022-07-18 Mirati Therapeutics Inc Inibidores de prc2
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
CA3133004A1 (en) * 2019-05-31 2020-12-03 Sichuan Haisco Pharmaceutical Co., Ltd. Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN110964200A (zh) * 2019-12-19 2020-04-07 新纳奇材料科技江苏有限公司 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法
WO2021129629A1 (zh) * 2019-12-23 2021-07-01 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074642A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Chemical compounds
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN101341124A (zh) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环
US9023847B2 (en) * 2009-08-07 2015-05-05 Merck Patent Gmbh Azaheterocyclic compounds
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
PL2566327T3 (pl) 2010-05-07 2017-09-29 Glaxosmithkline Llc Indole
EP2566328B1 (en) * 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
US9730925B2 (en) * 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MX362339B (es) 2012-04-13 2019-01-11 Epizyme Inc Forma de sal de un inhibidor de histona metiltransferasa humana ezh2.
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
NZ630205A (en) * 2013-04-30 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Enhancer of zeste homolog 2 inhibitors

Also Published As

Publication number Publication date
PH12015502414A1 (en) 2016-02-22
AU2014261075A1 (en) 2015-11-05
EA201592068A1 (ru) 2016-05-31
ES2717680T3 (es) 2019-06-24
SG11201508203TA (en) 2015-11-27
CA2910873A1 (en) 2014-11-06
CN105308038A (zh) 2016-02-03
US20160102083A1 (en) 2016-04-14
US20170029412A1 (en) 2017-02-02
MX2015015144A (es) 2016-02-18
EP2991980B1 (en) 2019-01-02
WO2014177982A1 (en) 2014-11-06
AU2014261075B2 (en) 2017-01-19
US9505745B2 (en) 2016-11-29
JP2016517878A (ja) 2016-06-20
US9790212B2 (en) 2017-10-17
NZ630205A (en) 2017-03-31
HK1214815A1 (zh) 2016-08-05
JP6373973B2 (ja) 2018-08-15
EA030196B1 (ru) 2018-07-31
PE20151981A1 (es) 2016-01-14
KR20160003115A (ko) 2016-01-08
ZA201507398B (en) 2017-01-25
EP2991980A1 (en) 2016-03-09
DOP2015000270A (es) 2016-02-15
CN105308038B (zh) 2018-05-29
BR112015027527A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CO2018004124A2 (es) Compuestos heterocíclicos
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
CL2015000944A1 (es) Compuestos de benceno sustituido
EA201591532A1 (ru) Ингибиторы carm1 и их применение
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
ECSP18014798A (es) Inhibidores de ezh2
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112019006987A2 (pt) inibidores de receptor de glicocorticoide
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017022281A2 (pt) métodos para tratar câncer